Redwood Pharma and Prof. Gerhard Garhöfer of the Medical University of Vienna, Austria invite you to listen to the live presentation at 10:30 am CET today March 12, 2020 of the results of the RP101 Phase II clinical trial following this morning's formal press release.

The presentation will be held at the location: Kungstornen Konferens center, Kungsgatan 33, 2 tr, 111 56 Stockholm.

To view the webcast and ask questions, please follow the link: https://www.finwire.tv/webcast/redwood-pharma/12mars/

Webcast viewers can submit questions for the presenters via the webcast.

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company's first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma's strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on the Spotlight Stock Market  (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: www.redwoodpharma.com